Regeneron Pharmaceuticals (NASDAQ:REGN) Trading 4.7% Higher – Still a Buy?

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)’s stock price was up 4.7% during trading on Monday . The stock traded as high as $735.00 and last traded at $741.02. Approximately 273,511 shares were traded during trading, a decline of 55% from the average daily volume of 612,186 shares. The stock had previously closed at $707.51.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the company. Robert W. Baird reduced their price objective on Regeneron Pharmaceuticals from $940.00 to $759.00 and set a “neutral” rating on the stock in a research note on Wednesday, February 5th. Sanford C. Bernstein reduced their price target on shares of Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating on the stock in a research report on Tuesday, January 7th. Wolfe Research assumed coverage on shares of Regeneron Pharmaceuticals in a research report on Friday, November 15th. They issued an “outperform” rating and a $1,150.00 price objective for the company. Piper Sandler cut their target price on shares of Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an “overweight” rating on the stock in a research note on Monday, January 27th. Finally, UBS Group cut shares of Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and decreased their price target for the stock from $1,130.00 to $738.00 in a research report on Thursday, January 16th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have given a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $973.13.

Regeneron Pharmaceuticals Trading Down 3.6 %

The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95. The business’s fifty day simple moving average is $697.08 and its 200 day simple moving average is $842.19. The stock has a market cap of $78.51 billion, a price-to-earnings ratio of 18.76, a P/E/G ratio of 2.34 and a beta of 0.27.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, topping analysts’ consensus estimates of $11.21 by $0.86. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The business had revenue of $3.79 billion for the quarter, compared to analysts’ expectations of $3.76 billion. During the same period in the prior year, the firm earned $11.86 EPS. The business’s quarterly revenue was up 10.3% on a year-over-year basis. On average, research analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th will be paid a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a yield of 0.49%. The ex-dividend date is Thursday, February 20th. Regeneron Pharmaceuticals’s payout ratio is 2.30%.

Institutional Trading of Regeneron Pharmaceuticals

Hedge funds have recently bought and sold shares of the company. Rakuten Securities Inc. grew its holdings in Regeneron Pharmaceuticals by 380.0% in the 3rd quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 19 shares in the last quarter. Pinney & Scofield Inc. acquired a new position in Regeneron Pharmaceuticals during the 4th quarter worth $25,000. FSA Wealth Management LLC bought a new position in shares of Regeneron Pharmaceuticals in the third quarter worth $26,000. OFI Invest Asset Management acquired a new position in shares of Regeneron Pharmaceuticals during the fourth quarter valued at $28,000. Finally, Avalon Trust Co bought a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter valued at about $36,000. 83.31% of the stock is currently owned by institutional investors.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.